Skip to main content
. Author manuscript; available in PMC: 2009 Jul 15.
Published in final edited form as: Clin Cancer Res. 2008 Jul 15;14(14):4526–4531. doi: 10.1158/1078-0432.CCR-07-5048

Fig. 3.

Fig. 3

Survival comparison of the crossover patients. Results show OS benefit from on-study date for patients treated first with vaccine and then with vaccine plus nilutamide, compared to patients treated first with nilutamide and then with nilutamide plus vaccine, suggesting a benefit from combined therapy when vaccine is given early in disease process.